Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-08-22
2006-08-22
Qazi, Sabiha (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
C552S653000
Reexamination Certificate
active
07094774
ABSTRACT:
This invention provides a novel class of vitamin D related compounds, namely, the 2-alkylidene-19-nor-vitamin D derivatives, as well as a general method for their chemical synthesis. The compounds have the formula:where Y1and Y2, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R6and R8, which may be the same or different, are each selected from hydrogen, alkyl, hydroxyalkyl and fluoroalkyl, or when taken together represent the group —(CH2)x— where x is an integer from 2 to 5, and where the group R represents any of the typical side chains known for vitamin D type compounds. These 2-substituted compounds are characterized by relatively high intestinal calcium transport activity and relatively high bone calcium mobilization activity resulting in novel therapeutic agents for the treatment of diseases where bone formation is desired, particularly low bone turnover osteoporosis. These compounds also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as anti-cancer agents and for the treatment of diseases such as psoriasis.
REFERENCES:
patent: 4666634 (1987-05-01), Miyamoto et al.
patent: 5086191 (1992-02-01), DeLuca et al.
patent: 5237110 (1993-08-01), DeLuca et al.
patent: 5246925 (1993-09-01), DeLuca et al.
patent: 5536713 (1996-07-01), DeLuca et al.
patent: 5587497 (1996-12-01), DeLuca et al.
patent: 5817648 (1998-10-01), Kutner et al.
patent: 5843927 (1998-12-01), DeLuca
patent: 5843928 (1998-12-01), Deluca et al.
patent: 5846960 (1998-12-01), Labrie
patent: 5849726 (1998-12-01), Brenner
patent: 5877168 (1999-03-01), Miyamoto et al.
patent: 5936133 (1999-08-01), DeLuca et al.
patent: 5945410 (1999-08-01), DeLuca et al.
patent: 5972917 (1999-10-01), Bishop et al.
patent: 6277837 (2001-08-01), DeLuca et al.
patent: 6316642 (2001-11-01), DeLuca et al.
patent: 6369099 (2002-04-01), DeLuca et al.
patent: 6372731 (2002-04-01), Kirsch et al.
patent: 6392071 (2002-05-01), DeLuca et al.
patent: 6440953 (2002-08-01), DeLuca et al.
patent: 6458827 (2002-10-01), DeLuca et al.
patent: 6482812 (2002-11-01), DeLuca et al.
patent: 6503893 (2003-01-01), Bishop et al.
patent: 6506912 (2003-01-01), DeLuca et al.
patent: 6537981 (2003-03-01), DeLuca et al.
patent: 6544969 (2003-04-01), DeLuca et al.
patent: 6566351 (2003-05-01), Ogata et al.
patent: 6566352 (2003-05-01), DeLuca et al.
patent: 6573256 (2003-06-01), Bishop et al.
patent: 6579861 (2003-06-01), DeLuca et al.
patent: 6627622 (2003-09-01), DeLuca et al.
patent: 6667298 (2003-12-01), DeLuca et al.
patent: 6680309 (2004-01-01), Bishop et al.
patent: 6696431 (2004-02-01), DeLuca et al.
patent: 6806262 (2004-10-01), DeLuca et al.
patent: 6835723 (2004-12-01), DeLuca et al.
patent: 6887860 (2005-05-01), DeLuca et al.
patent: 0184206 (1985-12-01), None
patent: 0078704 (1987-04-01), None
patent: 0387077 (1990-09-01), None
patent: 0480572 (1992-04-01), None
patent: 0474517 (1992-11-01), None
patent: 0516410 (1992-12-01), None
patent: WO90/09991 (1990-09-01), None
patent: WO96/01811 (1996-01-01), None
Baggiolini et al, “Stereochemical Total Synthesis of 1a,25-Dihydroxycholecalciferol and 1Beta,25-Dihydroxyerocalciferol”, Journal of Organic Chemistry, 51, pp. 3098-3108, 1986.
Bouillon et al, “Biological Activity of Dihydroxylated 19-Nor-(Pre)Vitamin D3”, Bioactivity of 19-Nor-Pre D, vol. 8, No. 8, pp. 1009-1015, 1993.
Chemical Abstracts, “Chemistry of Synthetic High Polymers”, vol. 110, No. 10, Abstract 110: 82505v, Mar. 6, 1989.
Chemical Abstracts, XP-002066055, vol. 121, No. 21, Nov. 21, 1994.
Fujishima et al, “Synthesis and Biological Activity of 2-Methyl-20-EPI Analogues of 1Alpha,25-Dihydroxyvitamin D3,” Bioorganic & Medicinal Chemistry Letters, 8, pp. 2145-2148, 1998.
Kiegiel et al, “Chemical Conversion of Vitamin D3 to its 1,25-Dihydroxy Metabolite”, Tetrahedron Letters, vol. 31, No. 43, pp. 6057-60660, 1991.
Konno et al, “A Novel and Practical Route to A-Ring Enyne Synthon for 1Alpha,25-Dihydroxyvitamin D3 Analogs: Synthesis of A-ring Diastereomers of 1Alpha,25-Dihydroxy-Vitamin D3 and 2-Methyl-1,25-Dihydroxyvitamin D3,” Bioorganic & Medicinal Chemistry Letters, 8, pp. 151-156, 1998.
Okano et al, “Regulatory Activities of 2b-(3-Hydroxypropoxy)-1a,25-Dihydroxyvitamin D3, A Novel Synthetic Vitamin D3 Derivative on Calcium Metabolism”, Biochemical and Biophysical Research Communications, vol. 163, No. 3, pp. 1444-1449, Sep. 29, 1989.
Perlman et al, “1a,25-Dihydroxy-19-Nor-Vitamin D3. A Novel Vitamin D-Related Compound with Potential Therapeutic Activity”, Tetrahedron Letters, vol. 31, No. 13, pp. 1823-1824, Feb. 1990.
Posner et al, “2-Fluoroalkyl A-Ring Analogs of 1,25-Dihydroxyvitamin D3-Stereocontrolled Total Synthesis via Intramolecular and Intermolecular Diels-Alder Cycloadditions. Preliminary Biological Testing”, Journal of Organic Chemistry, 60, pp. 4617-4628, 1995.
Posner et al, “Stereocontrolled Synthesis of a Trihydroxylated A Ring as an Immediate Precursor to 1Alpha,2Alpha,25-Trihydroxyvitamin D3”, Journal of Organic Chemistry, 56, pp. 4339-4341, Apr. 15, 1995.
Sarandeses et al, “Synthesis of 1Alpha,25-Dihydroxy-19-Norprevitamin D3”, tetrahedron Letters, pp. 5455-5448, Apr. 1992.
Sicinski et al, “New 1Alpha,25-Dihydroxy-19-Norvitamin D3 Compounds of High Biological Activity: Synthesis and Biological Evaluation of 2-Hydroxymethyl, 2-Methyl, and 2-Methylene Analogues,” Journal of Medical Chemistry, 41, pp. 4662-4674, 1998.
Slatopolsky et al, “A New Analog of Calcitriol, 19-Nor-1,25-(OH)2 D2 Suppresses Parathyroid Hormone Secretion in Uremic Rats in the Absence of Hypercalcemia”, American Journal of Kidney Disorders, 26(5), 832-860, 1995.
Suhara et al, “Synthesis and Biological Evaluation of Novel 2Alpha-Substituted 1Alpha,25-Dihydroxyvitamin D3 Analogues,” Biolorganic & Medicinal Chemistry Letters, 10, pp. 1129-1132, Mar. 16, 2000.
DeLuca Hector F.
Sicinski Rafal R.
Andrus Sceales Starke & Sawall LLP
Qazi Sabiha
Wisconsin Alumni Research Foundation
LandOfFree
26,27-homologated-20-epi-2-alkylidene-19-nor-vitamin D... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 26,27-homologated-20-epi-2-alkylidene-19-nor-vitamin D..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 26,27-homologated-20-epi-2-alkylidene-19-nor-vitamin D... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3626250